Press "Enter" to skip to content

Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer – BioSpace

admin 0

Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer  BioSpace

PLYMOUTH MEETING, Pa., June 26, 2019 /PRNewswire/ — Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the completion of target enrollment …

“cervical cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *